Distribution of Immune Cells and Their Subtypes in Peripheral Blood of Gout

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate whether immune cells and their subtypes in peripheral blood affects the asymptomatic hyperuricemia, gout flare, intercritical gout and advanced gout.

Detailed Description
-----------------
A number of studies have reported that innate immunity cells (such as blood monocytes and neutrophils) play a crucial role in the initiation and amplification of gout flare resulted from MSU deposition in the joint or tissue, leading to release NLRP3 inflammasome-mediated production of bioactive IL-1β. Further investigation demonstrated the role of blood neutrophils might contribute to the resolution of gout flare by forming aggregated neutrophil extracellular traps. Recently, a few in vitro experiments have indicated that adaptive immunity may be involved in mechanisms of gout. However, a global understanding of blood immune responses underlying gout is still unclear. Thus, we want to investigate the relationship between immune cells and their subtypes in peripheral blood and the gout.

Official Title
-----------------
Distribution of Immune Cells and Their Subtypes in Peripheral Blood of Gout

Conditions
-----------------
Gout Flare, Intercritical Gout, Advanced Gout, Asymptomatic Hyperuricemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: gout flare:diagnosis with gout flare at this hospital according to the criteria approved by the ACR Board of Directors and the EULAR Executive Committee in 2015 intercritical gout: remission of gout patients were classified into intercritical gout group without tophi, chronic gouty arthritis, or imaging erosion(All of these gout remission patients underwent dual-energy CT test within one month, and were detected to have MSU crystal deposition in local joints) advanced gout: gout remission patients were classified into advanced gout group characterized by tophi, chronic gouty arthritis, or imaging erosion(All of these gout remission patients underwent dual-energy CT test within one month, and were detected to have MSU crystal deposition in local joints) asymptomatic hyperuricemia: hyperuricemia in men was defined as SUA ≥ 420 mmol/L without any complications Exclusion Criteria: primary osteoarticular diseases unwilling participation in the study corticosteroids or indomethacin use in the past 3 months; septic arthritis or another joint disease (such as rheumatoid arthritis); impaired renal function (creatinine clearance <30 mL/min) and other conditions which may increase the level of blood uric acid

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| remission of gout | Patients fulfilling all the domains of the 2016 preliminary remission criteria for gout were defined as gout remission group | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PBMC monocyte Treg